Progress in Alzheimer's and Parkinson's Diseases, Softcover reprint of the original 1st ed. 1998
Advances in Behavioral Biology Series, Vol. 49

This book represents the fourth ina series of international conferences related to Alzheimer's (AD) and Parkinson's (PO) diseases. The first one took place in EHat, Israel in 1985; the second in Kyoto, Japan, in 1989; and the third in Chicago, IL, USA in 1993. This book incorporates the proceedings of the Fourth International Conference on Pro­ gress in Alzheimer's and Parkinson's Diseases, held in EHat, Israel, on May 18-23, 1997. This Conference was the 41st in the series of annual OHOLO Conferences sponsored by the Israel Institute for Biological Research (IIBR). It was also conducted under the aus­ pices of the Alzheimer's Association Ronald and Nancy Reagan Research Institute, USA. The Conference was attended by 550 participants from 28 countries, representing a broad spectrum of research interests; and included a well-balanced representation from aca­ demia, clinical institutions and pharmaceutical industry. The four-and-one-half day meeting served as an excellent medium for surveying the current preclinical and clinical develop­ ments in AD, PO, and other related disorders. The scientific program was divided into 24 oral sessions and daily poster sessions. The conference culminated in a round table discus­ sion. There were 122 talks and 161 posters. This book incorporates a combination of both.

Pathology in Alzheimer's Disease: General: 1. The Pathogenesis of Alzheimer's Disease; R.D. Terry. 2. Molecular and Cellular Abnormalities of Tau in Early Alzheimer's Disease; P. Davis, et al. Apoliprotein E: 3. ApoE and Memory in Alzheimer's Disease; H.S. Soininen, P.J. Riekkinen, Sr. 4. Divergent Metabolism of Apolipoproteins E3 and E4 by Cells; R.E. Pitas, et al. 5. APP, ApoE, and Presenilin Transgenics: Toward a Genetic Model of Alzheimer's Disease; L. Pradier, et al. Apoptosis; Oxidative Stress; Amyloids, Inflammation and Other Defects: 8. Apoptosis in Alzheimer's Disease: Inductive Agents and Antioxidant Protective Factors; C.W. Cotman, C.J. Pike. 9. Membrane Constituencies and Receptor Subtype Contribute to Age-Related Increases in Vulnerability to Oxidative Stress: Implications for Neurodegenerative Disease; J.A. Joseph, et al. 10. Mitochondrial Dysfunction and Alzheimer's Disease; S.S. Ghosh, et al. 11. Mitochondrial Dysfunction in Parkinson's Disease: Potential Applications for Cybrid Modeling of the Disease; R.H. Swerdlow, et al. Amyloid Aggregation: 27. Amyloid-beta Hypothesis of Alzheimer's Disease; M.S. Shearman. 28. Discovery and Characterization of Peptidoorganic Inhibitors of Amyloid beta-Peptide Polymerization; M.A. Findeis, S.M. Molineaux. 29. Anthracyclines and Amyloidosis; C. Post, et al. 30. The Amino Terminus of the beta-Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility; B. Solomon, et al. 31. Animal Models of Amyloid Aggregation and Deposition; R. Kisilevsky Tau in Alzheimer's Disease: 32. The Conformations of Tau Protein and Its Aggregation into Alzheimers Paired Helical Filaments; E. Mandelkow, et al. Alzheimer's Disease/Parkinsons's Disease and Related Disorders: Clinical and Etiological Aspects: 37. Different Cognitive Profiles on Memory Tests in Parkinson's Disease and Alzheimer's Disease; R.F. Allegri, et al. Parkinson's Disease&endash;Etiology, Genetics, Treatment: 56. Genetic Aspects of Parkinson's Disease; Y. Mizuno, et al. Cholinergic Strategies in Alzheimer's and Parkinson's Disease: 64. The Rationale for Development of Cholinergic Therapies in AD; A. Enz, P.T. Francis. Alzheimer's Disease&endash;Muscarinic Treatment and Therapy&endash;beta-Amyloids: 70. APP Localization and Trafficking in the Central Nervouse System; J.D. Buxbaum, et al. Cholinesterase Inhibitors for Treatment of Alzheimer's Disease: 75. Crystallographic Studies on Complexes of Acetylcholinesterase with the Natural Cholinesterase Inhibitors Fasciculin and Huperzine A; I. Silman, et al. Neurotrophic Factor Therapy&endash;Neuroprotection, Neurotransplantation and Other Treatment Strategies: 86. Functional Effects of GDNF on Dopamine Neurons in Animal Models of Parkinson's Disease; A.F. Hoffman, et al. Animal Models in Alzheimer's and Parkinson's Diseases: 93. Age Dependence of Muscarinic Plasticity in the Rat Hippocampus; J.M. Auerbach, M. Segal. Diagnostic Too